# Single Dose Escalation Study FTIM in Order to Assess Safety and Tolerability of GSK610677

> **NCT00694902** · PHASE1 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 24 (actual)

## Conditions studied

- Pulmonary Disease, Chronic Obstructive

## Interventions

- **DRUG:** GSK610677
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00694902
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-05-26
- **Primary completion:** 2008-09-23
- **Final completion:** 2008-09-23
- **Target enrollment:** 24 (ACTUAL)
- **Last updated:** 2017-08-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00694902

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00694902, "Single Dose Escalation Study FTIM in Order to Assess Safety and Tolerability of GSK610677". Retrieved via AI Analytics 2026-06-15 from https://api.ai-analytics.org/clinical/NCT00694902. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*